A woman who had life-changing results on a popular weight loss drug struggled to afford it for years.
AdvertisementTara Rothenhoefer, a 49-year-old Florida resident, says her life changed when she joined a clinical trial for a promising new weight-loss medication.
While regulated, these compounded drugs aren't FDA-approved, raising concerns from doctors about variations in quality.
The grey market of weight-loss drugs is vast and complicated.
In August, Eli Lilly halved the price of its weight-loss drug Zepbound through single-dose vials — a bid to lure customers back to brand-name drugs, analysts said.
Persons:
—, Tara Rothenhoefer, Rothenhoefer, Eli Lilly, She's
Organizations:
Service, Novo Nordisk's, Research, FDA, Pharmaceutical
Locations:
Florida